Valuation: Glaukos Corporation

Market Cap 14.49B 13.15B 12.15B 10.96B 20.69B 1,354B 21.49B 146B 57.91B 730B 54.36B 53.22B 2,308B P/E 2026 *
-980x
P/E 2027 * 186x
Enterprise Value 14.34B 13.02B 12.03B 10.85B 20.48B 1,340B 21.26B 145B 57.31B 723B 53.8B 52.67B 2,284B EV / Sales 2026 *
18.4x
EV / Sales 2027 * 14.1x
Free-Float
95.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week+4.28%
Current month+3.67%
1 month+47.53%
3 months+32.70%
6 months+73.24%
Current year+118.15%
1 week 237.54
Extreme 237.54
250.61
1 month 164.08
Extreme 164.085
255.18
Current year 93.96
Extreme 93.96
255.18
1 year 87.32
Extreme 87.3196
255.18
3 years 59.22
Extreme 59.22
255.18
5 years 33.33
Extreme 33.33
255.18
10 years 23.08
Extreme 23.075
255.18
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
Director of Finance/CFO 50 05/05/2017
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap. Importance
4/11/26 Exercice

Director

7,500 0.0131%
30/10/26 Don

Director

-4,764 0.0083%
30/10/26 Exercice

Executive/Senior Manager

70,374 0.1227%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+4.28%+178.63%+284.50% 14.49B
-1.14%-3.74%-18.23%+6.81% 186B
+0.35%+1.65%+7.26%+38.14% 126B
+1.88%-2.66%-12.35%+9.46% 118B
-3.09%-4.69%-43.35%-0.32% 93.33B
-1.12%+1.34%-3.18%+81.23% 68.11B
-0.10%+1.67%+13.19%-7.33% 58.96B
-0.83%-0.17%+3.95%+49.98% 55.2B
-0.45%+0.41%-3.74%+42.17% 48.58B
-0.55%-0.13%+0.65%-1.09% 35.56B
Average -0.47%+0.87%+12.28%+50.35% 80B
Weighted average by Cap. -0.46%-0.76%-5.93%+26.29%

Financials

2026 *2027 *
Net sales 781M 709M 655M 590M 1.11B 72.93B 1.16B 7.89B 3.12B 39.35B 2.93B 2.87B 124B 1B 911M 842M 759M 1.43B 93.76B 1.49B 10.14B 4.01B 50.59B 3.76B 3.69B 160B
Net income -17.36M -15.76M -14.56M -13.14M -24.8M -1.62B -25.75M -175M -69.4M -875M -65.15M -63.78M -2.77B 76.26M 69.23M 63.95M 57.69M 109M 7.13B 113M 771M 305M 3.84B 286M 280M 12.15B
Net Debt -149M -135M -125M -113M -213M -13.95B -221M -1.51B -597M -7.53B -560M -548M -23.78B -298M -270M -250M -225M -425M -27.81B -441M -3.01B -1.19B -15.01B -1.12B -1.09B -47.42B
Projected Income Statement - Annual - Glaukos Corporation
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
18/11/26 USD 245.09 +0.09% 298,271
16/11/26 USD 244.88 -0.34% 865,459
13/11/26 USD 245.72 -0.13% 546,460
12/11/26 USD 246.03 -0.46% 808,479
11/11/26 USD 247.16 +4.64% 915,622
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Glaukos Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
244.88USD
Average target price
243.85USD
Spread / Average Target
-0.42%
  1. Stock Market
  2. Stocks
  3. GKOS Stock